Mr. George Achilleos reports

NETRAMARK DELIVERS TRANSFORMATIONAL QUARTER OF EXECUTION

Netramark Holdings Inc. has provided a business update highlighting significant progress across commercial execution, regulatory engagement and scientific validation. Collectively, these milestones strengthen the company's growth trajectory and reinforce Netramark's positioning in AI-driven (artificial intelligence) clinical trial optimization.

Key highlights:

• Contract backlog increases: Netramark's contract backlog increased to approximately $2.5-million during the quarter driven by new project commitments and continued commercial momentum. This growth reflects increasing demand for the company's NetraAI platform and supports Netramark's previously stated objective of reaching $8-million to $10-million in contract backlog by mid-2026.
• Major channel partner onboarding: Following the execution of a master services agreement with Worldwide Clinical Trials on April 3, 2025, Netramark completed Worldwide's onboarding and quality assurance process in mid-October. As a result, Netramark can now be actively included in Worldwide's phase 2 and phase 3 bids across central nervous system (CNS) and oncology, expanding the company's access to late-stage clinical development opportunities through a global contract research organization.
• Regulatory milestone -- U.S. Food and Drug Administration (FDA) critical path innovation meeting (CPIM): In December, Netramark completed a CPIM with the FDA. The CPIM was a non-regulatory, non-binding scientific exchange during which the FDA provided feedback on NetraAI -- Netramark's explainable AI/ML (machine learning) platform -- and discussed its application as an enrichment methodology in clinical trial design. The FDA provided feedback on NetraAI's approach to prespecified, alpha-controlled predictive enrichment and discussed considerations for identifying responder-enriched subgroups while maintaining control of Type I error, consistent with FDA enrichment guidance. The FDA also discussed how NetraAI differs from complex adaptive designs, Bayesian methods or computer-simulation-based approaches that are excluded from eligibility for the FDA's model-informed drug development (MIDD) paired meeting program and suggested that Netramark consider exploring the MIDD paired meeting program as an avenue for scientific dialogue alongside a pharmaceutical sponsor. CPIM discussions are drug product independent and do not constitute FDA endorsement of NetraAI or any product or service provided by the company.
• Nature portfolio publication: On Dec. 8, 2025, Netramark announced that its scientific study highlighting NetraAI was accepted for publication in npj Digital Medicine, part of the Nature Portfolio. The peer-reviewed paper, co-written with researchers from the U.S. National Institute of Mental Health (NIMH), demonstrates how NetraAI's explainable methodology identified clinically meaningful persona subgroups in a phase II depression trial, resulting in improved patient stratification and treatment response interpretation. Acceptance by a high-impact Nature journal provides third party validation of Netramark's scientific approach.
• Strategic research collaboration -- CAMH: During the quarter, Netramark, in collaboration with the Centre for Addiction and Mental Health (CAMH), was awarded a prestigious Ontario Research Fund -- Research Excellence (ORF-RE) Award, recognizing innovative research partnerships in Ontario. Under this collaboration, NetraAI is being deployed within CAMH's secure computing environment to analyze genetic and epigenetic data in schizophrenia and major depressive disorder. The work is focused on identifying explainable patient subpopulations and is expected to further strengthen NetraAI's capabilities in psychiatric indications and its relevance for pharmaceutical sponsors.

George Achilleos, chief executive officer of Netramark stated: "This quarter reflects disciplined execution across key areas of our business. We are seeing growing commercial traction, constructive scientific engagement with the FDA regarding NetraAI's regulatory positioning, and increasing third party validation through peer-reviewed publication and academic recognition, including our recent research award with CAMH. Completion of our onboarding with Worldwide Clinical Trials further expands our commercial reach and strengthens our route to market. Together, these milestones reinforce that our approach is both novel and increasingly aligned with the direction of modern clinical development. We remain focused on entering into new contracts, shortening sales cycles and helping sponsors derisk late-stage trials while advancing effective therapies for patients."

Outlook

With a strong start to fiscal 2026, Netramark is reiterating its previously stated guidance of achieving $8-million to $10-million in booked contract backlog by mid-2026.

This outlook is subject to assumptions and is supported by a growing base of direct client engagements, expanding channel partnerships and an active pipeline of late-stage opportunities. The company enters 2026 with increasing commercial momentum and a solid foundation for expected continued growth.

About NetraAI

In contrast to other AI-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small data sets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. The NetraAI uses explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses and adverse events), potentially increasing the likelihood of a clinical trial's success. Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to overfitting, which drowns out critical information that could have been used to improve a trial's chance of success.

About Netramark Holdings Inc.

Netramark is a company focused on being a leader in the development of generative artificial intelligence/machine learning solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that can parse patient data sets into subsets of people who are strongly related across several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activate traditional AI/ML methods. The result is that Netramark can work with much smaller data sets and accurately segment diseases into different types as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.